PetVivo Hldgs Q1FY27 Results: Revenue up 13%, net loss narrows 30%
- Revenue grew 13% YoY to $338,000, driven by flagship Spring product sales
- Net loss narrowed 30% YoY to $1.7 million as operating expenses fell 10%
- Gross margin expanded to 66% from 63% following discontinuation of lower-margin licensed products
- Cash position stands at $123,000, with expected inflow of $1.35 million from equity subscription
- Company announced acquisition of Piezobio Membrane to boost R&D and grant opportunities
*this image is generated using AI for illustrative purposes only.
PetVivo Holdings (OTC: PETV) reported a 13% year-over-year increase in revenue for the first quarter of fiscal 2027, ending June 30, 2026. The topline growth was driven by sales of its flagship product, Spring with OsteoCushion Technology, as the company shifted focus away from licensed products.
Financial Performance
Revenue for the quarter totaled $338,000, up from $300,000 in the same period last year. This represents a 33% sequential increase from the previous quarter. The company discontinued sales of the Precise PRP product line from VetStem, focusing exclusively on its proprietary Spring product.
| Metric | Q1FY27 | Q1FY26 | Change |
|---|---|---|---|
| Revenue | $338,000 | $300,000 | +13% YoY |
| Gross Profit | $223,000 | $187,000 | +19% YoY |
| Gross Margin | 66% | 63% | +300 bps |
| Operating Expenses | $1.8 million | $2.0 million | -10% YoY |
| Net Loss | $1.7 million | $2.3 million | -30% YoY |
Gross profit rose to $223,000, improving the gross margin to 66% from 63% in the prior year. Management attributed this expansion to the higher-margin profile of the Spring product compared to the discontinued Precise PRP line.
Total operating expenses decreased 10% to $1.8 million. This reduction was primarily due to a 31% drop in research and development (R&D) expenses and a 9% decline in general and administrative costs. These savings were partially offset by a 2% increase in sales and marketing expenses.
The operating loss narrowed 13% to $1.6 million. Consequently, the net loss improved 30% to $1.7 million ($0.05 per share), compared to a net loss of $2.3 million ($0.10 per share) in the year-ago period.
What the Numbers Show
The improvement in the bottom line was significantly aided by non-operational factors. Interest expense fell sharply to $5,000 from $122,000 in the prior year. Additionally, the company recorded no unrealized loss on derivative liabilities, avoiding the $320,000 hit seen in the same period last year. Excluding these non-recurring benefits, the operational contribution to the net loss reduction was driven by the 10% cut in operating expenses against a 13% revenue gain.
Balance Sheet and Cash Flow
Cash used in operating activities decreased substantially to approximately $966,000, a 40% reduction from the prior year. This efficiency gain was largely due to better utilization of accounts payable and accrued expenses.
Cash at the end of the quarter stood at $123,000, down from $201,000 at the end of the previous fiscal year. However, management expects the cash position to increase as an investor completes a remaining subscription commitment of $1,350,000 from an equity offering.
Strategic Developments
PetVivo announced an agreement to acquire Piezobio Membrane (PBM), a developer of functional biomaterials and piezoelectric technologies. The acquisition aims to enhance product development capabilities and open opportunities for government grants and research collaborations. The company has filed for a federal government grant in collaboration with PBM and the University of Connecticut to fund the advancement of five unique technologies.
Internationally, Health Canada officially recognized Spring with OsteoCushion Technology as a veterinary medical device authorized for commercialization. PetVivo is now developing a distributor network for Canada, expecting to secure relationships within the next month or two.
The company also advanced its PetVivo AI veterinary practice platform, powered by Digitalandia’s Agentic Pet technology. Currently in beta, the platform claims to reduce customer acquisition costs by 50% to 90%. A full commercial launch is expected within the next few months.
How will the $1.35 million equity subscription impact PetVivo's cash runway and dilution per share given the current $123,000 cash balance?
What is the projected timeline and revenue contribution for the PetVivo AI platform following its expected commercial launch in the coming months?
Will the acquisition of Piezobio Membrane require additional capital expenditure, and how might the pending federal grant influence R&D spending trends?
16
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
